Lead Sponsor

Bayer

Age

15 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patients with advanced (unresectable, recurrent or metastatic) RCC
•Patients reasonably likely to benefit from treatment with sorafenib as a single agent therapy
•Patients with an ECOG performance status of 0-2
•Patients who will not require other systemic anticancer therapy (except for bisphosphonates) while taking sorafenib
•Patients with vascular diseases such as wet macular degeneration, vasculitis, or new peptic ulcer, may be enrolled but require close monitoring in accordance with established medical practice

•Patients who are currently enrolled in, are eligible for, or have access to, any other sorafenib clinical trial
•Patients who have participated in any other sorafenib trial
•Patients who have had prior therapy with investigational agent(s) within the last four weeks prior to study entry
•Life expectancy of less than two months
•Patients with cardiac arrhythmias greater than grade 1 NCI CTCAE, Version 3.0
•Patients with active coronary artery disease or ischemia
•Patients with Child-Pugh class C hepatic impairment
•Patients with severe renal impairment or who require dialysis
•Patients with active uncontrolled hypertension
•Patients with recent or active bleeding diathesis

Related studies

NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more

NCT04895709 · Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, and more

NCT07227415 · Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, and more

NCT07166445 · Carcinoma, Renal Cell, Diagnostic Imaging, and more

NCT05127824 · Carcinoma, Renal Cell

Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma